文献速递骨质疏松与代谢性骨病

双膦酸盐药物假期对骨密度及骨质疏松性骨折风险影响的系统综述与荟萃分析

A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
PubMed 文献 · Osteoporos Int · 2019-01-08

该系统综述与荟萃分析纳入8项研究共13条记录,评估双膦酸盐药物假期(停药)对比持续治疗对骨密度和骨折风险的影响。荟萃分析显示停药女性髋部骨折(HR 1.09,95%CI 0.87-1.37)和任何临床骨折(HR 1.13,95%CI 0.75-1.70)风险与持续用药者无显著差异。作者认为初始治疗3-5年后髋部骨密度不低的女性可考虑停药,而髋部骨密度低者可能从持续治疗中获益。

要点

  • FLEX研究显示阿仑膦酸钠治疗10年较5年降低临床椎体骨折风险(RR 0.45,95%CI 0.24-0.85)。
  • HORIZON扩展研究显示唑来膦酸治疗6年较3年降低形态学椎体骨折风险(OR 0.51,95%CI 0.26-0.95)。
  • 停药女性髋部骨折(HR 1.09,95%CI 0.87-1.37)和任何临床骨折(HR 1.13,95%CI 0.75-1.70)风险与持续用药者无显著差异。

核心结论

  • 初始治疗3-5年后髋部骨密度不低的女性可考虑双膦酸盐停药,而髋部骨密度低者可能从持续治疗中获益。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library数据库,纳入评估药物假期/停药对比骨质疏松治疗继续的对照临床试验和队列研究,共13条记录来自8项不同研究符合纳入标准。

主要发现

  • FLEX研究显示阿仑膦酸钠治疗10年较5年降低临床椎体骨折风险(RR 0.45,95%CI 0.24-0.85)。
  • HORIZON扩展研究显示唑来膦酸治疗6年较3年降低形态学椎体骨折风险(OR 0.51,95%CI 0.26-0.95)。
  • 亚组分析显示初始治疗期后髋部骨密度T值低的女性从持续治疗中获益,表现为椎体骨折风险降低。
  • 停药女性对比持续用药者,髋部骨折风险荟萃HR 1.09(95%CI 0.87-1.37),任何临床骨折风险荟萃HR 1.13(95%CI 0.75-1.70),均无显著差异。

关键数值与推荐

  • 初始治疗3-5年后髋部骨密度不低的女性可考虑双膦酸盐停药。
  • 髋部骨密度低的女性可能从持续治疗中获益。

临床怎么用

  • 作者认为初始治疗3-5年后无低髋部骨密度的女性可考虑双膦酸盐停药。
  • 作者认为髋部骨密度低的女性可能从持续治疗中获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We performed a systematic review on the effect of drug holidays (discontinuation) on bone mineral density (BMD) and fracture risk. Bisphosphonate discontinuation may be considered for women who do not have low hip BMD after 3-5 years of initial treatment, while women who have low hip BMD may benefit from treatment continuation. INTRODUCTION: We performed a systematic review and meta-analysis on the effect of drug holidays (discontinuation) on BMD and fracture risk. METHODS: We searched PubMed, Embase, and Cochrane Library databases to locate controlled clinical trials and cohort studies evaluating the effect of drug holidays/discontinuation versus osteoporosis treatment continuation. We performed random-effects meta-analyses of hazard ratios of hip and any clinical osteoporotic fracture for individuals who discontinued bisphosphonates compared to persistent users. RESULTS: Thirteen records reporting results from eight different studies met inclusion criteria. The FLEX study found a reduced clinical vertebral fracture risk with 10 years of alendronate therapy compared to 5 (RR 0.45, 95% CI 0.24-0.85), and the HORIZON extension studies found a reduced risk of morphometric vertebral fracture with 6 years of zoledronic acid therapy compared to 3 (OR = 0.51, 95% CI 0.26-0.95); subgroup analyses showed that women with low hip BMD T-scores after the initial treatment period benefitted from continued treatment in terms of reduced vertebral fracture risk. Meta-analysis of adjusted hazard ratios of hip and any clinical osteoporotic fracture for women who discontinued bisphosphonates revealed no significant differences in the risk of hip fracture (summary estimate of HR 1.09, 95% CI 0.87-1.37) or any clinical fracture (summary estimate of HR 1.13, 95% CI 0.75-1.70) compared to persistent users. CONCLUSIONS: Bisphosphonate discontinuation may be considered for women who do not have low hip BMD after 3 to 5 years of initial treatment, while women who have low hip BMD may benefit from treatment continuation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Nayak S, Greenspan SL. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int. 2019. PMID: 30623214. doi:10.1007/s00198-018-4791-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。